What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a peptide that mimics a gut hormone involved in post-meal signaling. Unlike most peptides discussed in wellness marketing, branded semaglutide products completed large-scale clinical programs and hold FDA approvals.
Brand names under FDA labeling include Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management and related labeled indications.1 An oral Wegovy tablet approval (reported December 2025) should be confirmed against the current FDA label before publication.2
Benefits & what it’s studied for
In obesity registration programs (e.g., STEP; OASIS for an oral formulation), average body-weight changes versus baseline/placebo were reported; magnitudes depend on product, dose schedule in the trial, adherence, and population. Trial averages are not individual promises.4
SUSTAIN and related diabetes programs reported improvements in glycemic measures (including HbA1c) in type 2 diabetes populations under study conditions.5
SELECT reported a reduction in major adverse cardiovascular events with semaglutide versus placebo in its studied population; see the trial publication and label for the precise estimate.3
FDA materials have described an accelerated-approval pathway indication related to metabolic dysfunction-associated steatohepatitis for semaglutide; confirm the live label text before publish.6
How does Semaglutide work?
Semaglutide activates the GLP-1 receptor. Pharmacology reviews describe effects on appetite signaling, gastric emptying, and glucose-dependent insulin secretion as part of the proposed pathway for the metabolic endpoints studied in trials.7
Dosing & administration
Approved semaglutide products have label-specified dose schedules that differ by brand and indication. Those details belong in the official prescribing information and a clinician’s care plan — not on this page.1
This is educational, not medical advice. Semaglutide is prescription-only. This site does not publish dosing ladders or administration instructions.
Risks, side effects & safety
Per product labeling, the most commonly reported adverse reactions include gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation. Labels also discuss pancreatitis, gallbladder disease, kidney injury related to volume depletion, hypoglycemia (especially with concomitant diabetes medicines), and a boxed warning for thyroid C-cell tumors; contraindications include personal or family history of medullary thyroid carcinoma or MEN 2, among other labeled restrictions.1
Withdrawal studies have reported weight regain after discontinuation under studied conditions.8
Legality & status
As of the draft date on this page, branded semaglutide products are FDA-approved and prescription-only. Branded semaglutide is not the same regulatory category as compounded semaglutide; the FDA has issued warnings about unapproved GLP-1 drugs.9 Related reporting: compounded vs approved framing.
Regulatory status as of June 2026 — reconfirm against the live FDA 503A list before go-live.
Thinking about Semaglutide?
Talk to a licensed provider who can tell you if it fits your goals — and build a safe protocol.
Research & references
- 1FDA labels / DailyMed — Ozempic, Rybelsus, Wegovy prescribing information. Link to be finalized. link pending
- 2FDA / Novo Nordisk — oral Wegovy approval (reported December 2025). Link to be finalized. link pending
- 3SELECT trial — semaglutide and cardiovascular outcomes. NEJM; link to be finalized. link pending
- 4STEP trials & OASIS 4 — weight-loss endpoints under study conditions. Link to be finalized. link pending
- 5SUSTAIN trials — glycemic endpoints in type 2 diabetes. Link to be finalized. link pending
- 6FDA / ESSENCE materials — MASH accelerated-approval indication (confirm live label). Link to be finalized. link pending
- 7GLP-1 receptor agonist pharmacology review. Link to be finalized. link pending
- 8STEP withdrawal literature — weight change after discontinuation. Link to be finalized. link pending
- 9FDA approval history + compounding warnings (unapproved GLP-1 drugs). Link to be finalized. link pending
Reference links are illustrative placeholders — replace with verified PubMed/journal URLs before publishing.
Frequently asked questions
Is semaglutide FDA-approved?+
Yes, under multiple brand labels for labeled indications that have included type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy), and other labeled uses described in current FDA materials. Confirm the live labels before publish.
What is the difference between Ozempic and Wegovy?+
Same active molecule (semaglutide), different FDA-approved indications and labeled dose schedules — Ozempic for diabetes contexts, Wegovy for weight-management contexts. Coverage and product selection are clinical and payer decisions.
Is compounded semaglutide the same as Wegovy?+
No. Branded semaglutide products are FDA-approved; compounded semaglutide is not an FDA-approved product and is regulated differently. The FDA has warned about unapproved GLP-1 drugs.
What do weight-loss trials report?+
Trials have reported average body-weight changes under study conditions; results vary by product, adherence, and population, and discontinuation studies have reported regain. Trial averages are not individualized outcomes.
Is semaglutide a peptide?+
Yes — it is a GLP-1 receptor agonist peptide that completed full FDA registration programs, unlike most peptides marketed only as research chemicals.